Avelox | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Avelox
US Patents

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

Bora Pharmaceuticals- Making success more certain.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Avelox

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

73 API Suppliers, 24 USDMF, 21 CEP/COS, 5 JDMF, 17 EU WC, 15 KDMF, 18 NDC API, 44 Listed Suppliers, $ API Reference Price

73 API Suppliers
24 USDMF
21 CEP/COS
5 JDMF
17 EU WC
15 KDMF
18 NDC API
44 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

91 FDF Dossiers, 28 FDA Orange Book, 28 Europe, 16 Canada, 2 South Africa, 17 Listed Dossiers

91 FDF Dossiers
28 FDA Orange Book
28 Europe
16 Canada
2 South Africa
17 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

RELATED EXCIPIENT COMPANIES

1 Minakem, 2 Rochem International Inc, 7 SPI Pharma, 2 Seqens, 7 DKSH, 3 Jai Radhe Sales, 1 Pharm-RX Chemical, 4 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 15 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 12 BASF, 2 Clariant, 10 Corel Pharma Chem, 1 Curia, 6 DFE Pharma, 1 Finar, 10 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 4 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 27 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders, 54 Coating Systems & Additives, 33 Direct Compression, 32 Disintegrants & Superdisintegrants, 29 Controlled & Modified Release, 27 Thickeners and Stabilizers, 22 Lubricants & Glidants, 22 Film Formers & Plasticizers, 22 Solubilizers, 18 Parenteral, 17 Co-Processed Excipients, 17 Granulation, 17 Topical, 12 Taste Masking, 10 Chewable & Orodispersible Aids, 9 Emulsifying Agents, 8 API Stability Enhancers, 7 Rheology Modifiers, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 1 Soft Gelatin

75 Fillers, Diluents & Binders
54 Coating Systems & Additives
33 Direct Compression
32 Disintegrants & Superdisintegrants
29 Controlled & Modified Release
27 Thickeners and Stabilizers
22 Lubricants & Glidants
22 Film Formers & Plasticizers
22 Solubilizers
18 Parenteral
17 Co-Processed Excipients
17 Granulation
17 Topical
12 Taste Masking
10 Chewable & Orodispersible Aids
9 Emulsifying Agents
8 API Stability Enhancers
7 Rheology Modifiers
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
4 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 18 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
18 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 18 Finished Drug Prices, 4 Annual Reports

3 US Medicaid Prescriptions
18 Finished Drug Prices
4 Annual Reports

MARKET PLACE

28 APIs, 1 FDF Dossiers

28 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 18 Health Canada Patents

2 US Patents
18 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 3 Others

2 EDQM
1 USP
3 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 391 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

2 All

01 2HARROW EYE

filter Patent Number Reset all filters

2 All

01 18450311

02 19114168

filter API Patent Reset all filters

2 All

01 2Blank

filter FDF Patent Reset all filters

2 All

01 2Y

filter Expiration Date Reset all filters

2 All

01 22029-05-29

Product Main Page

01

HARROW EYE

MOXIFLOXACIN HYDROCHLORIDE

Medlab Asia & Asia Health

Not Confirmed

HARROW EYE

Medlab Asia & Asia Health

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-05-29

MOXIFLOXACIN HYDROCHLORIDE

US Patent Number : 9114168

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22428

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-05-29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

HARROW EYE

MOXIFLOXACIN HYDROCHLORIDE

Medlab Asia & Asia Health

Not Confirmed

HARROW EYE

Medlab Asia & Asia Health

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-05-29

MOXIFLOXACIN HYDROCHLORIDE

US Patent Number : 8450311

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 22428

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-05-29

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?